Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that new data on ...
Crafting a winning ET AI Awards 2025 nomination requires more than technical excellence. It demands clarity of purpose, ...
Global pharma major Lupin Limited (Lupin) will present data from its phase 1a clinical trial evaluating LNP3693, a STING agonist, at the ESMO Congress in Berlin, Germany, from October 17 to October 21 ...
Visual content depicting climate activists emphasizes emotion and disruption, contrasting with the rational, data-driven ...
-- 11 new abstracts including MASH data to be presented at the 76th Annual AASLD The Liver Meeting (R), 7-11 November -- Highlights include data from post-hoc analyses of the ESSENCE trial ...
The randomized, double-blind, placebo-controlled, parallel-group Phase 2a M-ACCEL trial (ClinicalTrials.gov: (NCT05979779) evaluated HU6 at 150 mg, 300 mg, and 450 mg once daily for 26 weeks in adults ...
来自MSN
Boss takes credit for team's work on a big presentation, only to be publicly reprimanded by ...
He did the presentation with one slide only, lacking all the data, charts, insights, and results his employees put together. When the boss was done, his own boss asked about the actual analysis, and ...
Part 1 of this three-part series discusses common deception strategies school shooters use to influence others and evade ...
Regulatory debates: Enforcement variations: Differences in regulatory approaches to IAS 1 enforcement can lead to inconsistencies in financial reporting. This variability poses challenges for ...
WATERTOWN, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the ...
MASH data to be presented at the 76th Annual AASLD The Liver Meeting®, 7-11 November Highlights include data from post-hoc analyses ...
R&D Pipeline -- IND-enabling activities for a PSMA-targeted ADC are on track for completion by year-end, further expanding the development portfolio.
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈